Fusion Pharmaceuticals — Merger or Acquisition (November 2020)
26 slides from Fusion Pharmaceuticals's merger presentation, Nov 2, 2020
Slide 1: Fusion & AstraZeneca Strategic Collaboration
Exhibit 99.2 Fusion & AstraZeneca Strategic Collaboration To Develop and Commercialize Next-Generation Targeted Alpha Therapy Radiopharmaceuticals and Combination Therapies
Slide 2: Presenters
John Valliant, PhD Chief Executive Officer Marc Schwabish, PhD John Crowley, CPA SVP, BD and US Operations Chief Financial Officer % y Eric Burak, PhD James O’Leary, MD Chief Scientific Officer Chief Medical Officer
Slide 3: Forward-Looking Statements and Legal Disclaimers
Forward-Looking Statements and Legal Disclaimers rein deemed forward: ies statements. Without timing the ye oregon the words “expect,” ‘pane expressions are also intended to ident m ied Targeted Alpha ee or combination therapies for the treatment of various cancers; tis Reload and succes of any Futu
Slide 4: Collaboration Overview and Rationale
9 John Valliant, PhD Fusion Chief Executive Officer Collaboration Overview, and Rationale
Slide 5: Our Targeted Alpha Therapies Platform + AZ's Antibody & DDRi Portfolio
Our Targeted Alpha Therapies Platform + AZ’s Antibody & DDRi Portfolio Fusion setrazeneca,
Slide 6: Collaboration Overview
Collaboration Overview Fusien + Astrazeneca? 1) Novel Targeted Alpha Therapies e Jointly select up to three new TATs e Co-fund @ Co-develop @ Option to co-commercialize in U.S. 2) Combination Therapies with TATs e DNADamage Response Inhibitors (DDRis) @ Immuno-Oncology Agents e AZ solely funds unles
Slide 7: Fusion's Targeted Alpha Therapies Platform
jeted Alpha Thera Fusien FUSION’S TAT PLATFORM Proprietary ‘ : Precision Radio Pharma Fast-Clear™ + Antibodies + Medicine + Linker Imaging Manufacturing @ Particle of TATs Faster clearance from normal tissues improves therapeutic Actinium-228
Slide 8: Fusion + AstraZeneca
Fusien + AstraZeneca? @ Delivers access to breadth of AstraZeneca’s world-class oncology pipeline & products, resources and expertise e Avoids early-stage development risk @ Provides optionality around later-stage risk and expense @ Preserves significant back-end economics @ Maintains all rights to
Slide 9: Details of the Agreement
Pex Marc Schwabish, PhD Fusion Senior Vice President, Business Development and US Operations Details of the Agreement
Slide 10: Details of the Global Partnership Agreement
Details of the Global Partnership Agreement Fusion Therapeutic Expansion Business Model Maximize utilization Global partnership 1 four TAviplation Long-term agreement Maximize potential applications of Targeted Alpha radiation Therapies Fully-retain rights to our existing products Retain co-commerci
Slide 11: Overview of the Terms to Develop Novel TATs
w of the Terms to Develop Novel Up to three new TATs will be jointly selected and then... Co-developed with a 50/50 R&D cost split Each partner can opt-out at defined breakpoints in exchange for milestone payments to the other party and a low to high single- digit royalty on future sales a 1st > fol
Slide 12: Agreement to Develop Novel Clinical Combination Therapies
2) Agreement to Develop Novel Clinical Combination Therapies Fusion AstraZeneca Nominate for preclinical evaluation Responsible for TAT drug supply up to five targets Can opt-in to co-fund post-P1 Fully fund all R&D development (50/50) (unless Fusion opts-in to co-fund clin dev) If Fusion does not o
Slide 13: Scientific Rationale
pon Eric Burak, PhD Fusion Chief Scientific Officer Scientific Rationé
Slide 14: Using Antibodies in AstraZeneca's Leading Oncology Portfolio
1) Using Antibodies in AstraZeneca’s Leading Oncology Portfolio To Discover, Develop and Commercialize Up to Three Novel TATs FUSION’S TAT PLATFORM Proprietary Antibodies Precision Radio Pharma panice | Fast-Clear* - from AZ’s Leading -+ Medicine + R&D and ‘am sLinker Oncology Portfolio Imaging of T
Slide 15: Evaluate Up to Five Combination Therapy Programs Using TATs
2) Evaluate Up to Five Combination Therapy Programs Using TATs with is AZ’s Portfolio of Immuno-oncology Agents & DDRi INA Damage Response Inhibitors muno-Oncology Combo Therapy Imi Turning /O “resistant” tumors into /O “sensitive” BEFORE: AFTER: “Cold Tumor” “Hot Tumor” Immune Immune Responsive ast
Slide 16: TATs Are Synergistic with DNA Damage Response Inhibitors
TATs Are Synerg A Damage Response Inhibitors (DD! Single-Strand DNA Break e TATs + DDR inhibitors are a logical combination: here = TAT creates tumor DNA damage = DDRi prevents DNA repair Potential for increases in response rates and broader therapeutic utility Single-Strand DNA Break
Slide 17: Synergistic Efficacy with Olaparib vs Single Agent
peutic Single Agent ity FPI-1434 + Olaparib - CRC Xenograft Model FPI-1434 + Olaparib " BRCA Wild Type Combination ; Shows synergistic effects when compared to low-dose single agents alone © Vehicle —® Olaparib (25 mg/kg) 6 ot FPI-1434 (37 kBq/kg) + 37 KBqikg + 25 mgikg Synergistic Efficacy @ Has be
Slide 18: [225Ac] TAT + Checkpoint Inhibitors Demonstrate Enhanced Efficacy
Scientific Rationale: [?25Ac] TAT + Checkpoint Inhibitors Demonstrate Enhanced Efficacy in a Mouse Syngeneic Tumor Model Immune Competent Mouse ——_ CT-26 ~7 days Treat — Monitor (mulGF-1R", CTLA™, PD-1° Tumor) im ior — Tumor ~175 mm? oe Volume jose FPI-1792* with anti-CTLA-4 FPI-1792* with anti-PD-1
Slide 19: Reduced Tumor Growth Observed in All Dose Groups
Reduced Tumor Growth Observed in All Dose Groups Following Re-Challenge in Contralateral Flank Immune Competent Mouse Treat Re-Challenge CT-26 Colorectal Tumor — No Treatment, Monitor > Tumor (mulGF-1R**, CTLA**, PD-1* Tumor) (per previous slide) CT-26 Volume Vaccine Study: 13 of 15 Animals Showed N
Slide 20: Infiltration of Antigen-Specific CD8+ T Cells
Infiltration of Antigen-Specific CD8+ T Cells Is Responsible for “Vaccine Effect” Immune Competent Mouse Treat a Re-Challenge,_ No Treatment, Tumor! CT-26 Colorectal Tumor iy > Spleen (mulGF-1R™*, CTLA™, PD-1° Tumor) (per previous slide) CT-26 Assessment - tecti f Antigen-s ‘ific AH1 Tumor CD8+ T ce
Slide 21: Two Pillars of the Collaboration
Two Pillars of the Collaboration 1) Novel Targeted Alpha Therapies 2) Combination Therapies with TATs a a Particle @ Immuno- Oncology Agents + ores @ DNA Damage preaeoern raresting pone mareeting Response Isotope Antibodies: Isotope Antibodies Inhibitors (DDRis) New precision medicines Broader utili
Slide 22: Financials
John Crowley Fu: 3 Chief Financial Officer Financials Copyright© 2020 Fusion Pharmacoutcas Inc Al Rights Reserved
Slide 23: Agreement Drives Long-Term Value Creation
Agreement Drives Long-Term Value Creation Combinations bare TATs Opt Out for (up to 3) Each Novel TAT Fusi en Upto nomen Milestones Up to $40M $145M in milestones ($5M upfront) to Fusion from developer + Development 100% AZ nl 50/50 = AstraZeneca Expense (unless Fusion opts in Profit from Low-to-hig
Slide 24: Fusion + AstraZeneca
Fusien + AstraZeneca? @ Delivers access to breadth of AstraZeneca’s world-class oncology pipeline & products, resources and expertise e Avoids early-stage development risk @ Provides optionality around later-stage risk and expense @ Preserves significant back-end economics @ Maintains all rights to
Slide 25: Q&A
Q&A Fusion
Slide 26: Thank You
Thank You Fusion and AstraZeneca to Develop and C: jalize Next. Targeted Alpha Therapy Radiopharmaceuticals and Combination oes Copyright© 2020 Fusion Phama ine. A Rights Reserved
Fusion Pharmaceuticals — Merger or Acquisition (November 2020) on 6ix